A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of BMN 255 and to learn about the effect BMN
255 has on you and your hyperoxaluria associated with NAFLD, and compare these effects with a
placebo.
The primary safety objective of the study is to assess the safety and tolerability of daily
oral doses of BMN 255 in adult participants with NAFLD and hyperoxaluria.
The primary efficacy objective of the study is to assess 24-hour urine oxalate levels
(24-hour urine collection corrected for BSA) following daily oral doses of BMN 255 in adult
participants with NAFLD and hyperoxaluria.